GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cash, Cash Equivalents, Marketable Securities

ADMA Biologics (ADMA Biologics) Cash, Cash Equivalents, Marketable Securities : $45.3 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Cash, Cash Equivalents, Marketable Securities?

ADMA Biologics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($74.16 Mil) to Dec. 2023 ($51.35 Mil) but then stayed the same from Dec. 2023 ($51.35 Mil) to Mar. 2024 ($45.33 Mil).

ADMA Biologics's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($51.09 Mil) to Dec. 2022 ($86.52 Mil) but then declined from Dec. 2022 ($86.52 Mil) to Dec. 2023 ($51.35 Mil).


ADMA Biologics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ADMA Biologics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Cash, Cash Equivalents, Marketable Securities Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.75 55.92 51.09 86.52 51.35

ADMA Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.20 62.51 74.16 51.35 45.33

ADMA Biologics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


ADMA Biologics  (NAS:ADMA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


ADMA Biologics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics (ADMA Biologics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Executives
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp director, 10 percent owner 5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487